Poliumoside
(Synonyms: 金石蚕苷) 目录号 : GN10320
Poliumoside是一种咖啡酰化的苯丙烷类糖苷。
Cas No.:94079-81-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Poliumoside is a caffeoylated phenylpropanoid glycoside [1]. Poliumoside inhibits the formation of advanced glycation end products (AGEs, IC₅₀ = 19.69μM) and rat lens aldose reductase (RLAR, IC₅₀ = 8.47μM) [2]. Poliumoside has antioxidant and cell aggregation inhibitory effects [3-4].
In bone mesenchymal stem cells, Poliumoside (75μM, 150μM, 225μM, 300μM, 375μM; 24h) inhibits HGHF-induced BMSC ferroptosis [5]. In A549 cells, Poliumoside (10μM, 20μM, 40μM; 24h) alleviates TNF-α-induced cell damage by simultaneously regulating the NF-κB pathway and the Nrf2 pathway [6].
In Transient middle cerebral artery occlusion mouse model, Poliumoside (5mg/kg, 10mg/kg, 15mg/kg; ip; 3d) improves neurological function and reduces infarct volume after stroke [7]. In the cognitive dysfunction rat model, Poliumoside (5mg/kg, 10mg/kg; ip; 21d) treatment improved cognitive capacity in rats in morris water maze and recognition tests [8].
References:
[1]. He ZD, Lau KM, Xu HX, et al. Antioxidant activity of phenylethanoid glycosides from Brandisia hancei. Journal of ethnopharmacology. 2000 Aug 1; 71(3): 483-486.
[2]. Yu SY, Lee IS, Jung SH, et al. Caffeoylated phenylpropanoid glycosides from Brandisia hancei inhibit advanced glycation end product formation and aldose reductase in vitro and vessel dilation in larval zebrafish in vivo. Planta medica. 2013 Dec; 79(18): 1705-1709.
[3]. De Marino S, Festa C, Zollo F, et al. Antioxidant activity of phenolic and phenylethanoid glycosides from Teucrium polium L. Food Chemistry. 2012 Jul 1;133(1): 21-28.
[4]. Tatli II, Takamatsu S, Khan I, et al. Screening for free radical scavenging and cell aggregation inhibitory activities by secondary metabolites from Turkish Verbascum species [J]. Zeitschrift für Naturforschung C. 2007 Oct 1; 62(9-10): 673-678.
[5]. Xu CY, Xu C, Xu YN, et al. Poliumoside protects against type 2 diabetes-related osteoporosis by suppressing ferroptosis via activation of the Nrf2/GPX4 pathway. Phytomedicine. 2024 Mar 1; 125: 155342.
[6]. Zheng JN, Zhuo JY, Nie J, et al. Phenylethanoid glycosides from Callicarpa kwangtungensis Chun attenuate TNF-α-induced cell damage by inhibiting NF-κB pathway and enhancing Nrf2 pathway in A549 cells. Frontiers in pharmacology. 2021 Jul 7; 12: 693983.
[7]. Gao Y, Wang J, Zhang C, et al. Poliumoside alleviates microglia-mediated inflammation and blood-brain barrier disruption via modulating the polarization of microglia after ischemic stroke in mice. Phytomedicine. 2025 May 23: 156881.
[8]. Zuo Y, Chen B, Li X, et al. Poliumoside inhibits apoptosis, oxidative stress and neuro-inflammation to prevent intracerebroventricular Streptozotocin-induced cognitive dysfunction in Sprague-Dawley Rats: in in-vivo, in-vitro and in-silico study. Folia Morphologica. 2024 Oct 23.
Poliumoside是一种咖啡酰化的苯丙烷类糖苷 [1]。Poliumoside可抑制晚期糖基化终产物（AGEs，IC₅₀ = 19.69μM）和大鼠晶状体醛糖还原酶（RLAR，IC₅₀ = 8.47μM）的形成 [2]。Poliumoside具有抗氧化和抑制细胞聚集的作用 [3-4]。
在骨髓间充质干细胞中，Poliumoside（75μM、150μM、225μM、300μM、375μM；24h）可抑制人生长因子受体（HGHF）诱导的骨髓间充质干细胞（BMSC）铁死亡 [5]。在A549细胞中，Poliumoside（10μM、20μM、40μM；24h）通过同时调控NF-κB通路和Nrf2通路，减轻TNF-α诱导的细胞损伤 [6]。
在小鼠短暂性大脑中动脉闭塞模型中，Poliumoside（5mg/kg、10mg/kg、15mg/kg；ip；3d）可改善中风后的神经功能，减少梗死体积 [7]。在大鼠认知功能障碍的模型中，Poliumoside（5mg/kg、10mg/kg；ip；21d）治疗可改善大鼠在Morris水迷宫和识别测试中的认知能力 [8]。
| Cell experiment [1]: | |
Cell lines | Bone mesenchymal stem cells (BMSCs) |
Preparation Method | After BMSCs were treated with different Poliumoside concentrations for 24h, the existing culture medium was replaced with culture medium containing 10% CCK-8 reagent to form the surgical solution. Thereafter, the cells were incubated at a constant temperature of 37°C for 2h. |
Reaction Conditions | 75μM, 150μM, 225μM, 300μM, 375μM; 24h |
Applications | Poliumoside inhibits HGHF-induced BMSC ferroptosis. |
| Animal experiment [2]: | |
Animal models | Transient middle cerebral artery occlusion (tMCAO) mouse model |
Preparation Method | After tMCAO, Pol was injected intraperitoneally into mice and EDB was injected via the tail vein until the time of sacrifice. A total of 190 C57BL/6 mice were utilized in this study. In the initial experiment, mice were randomly divided into five groups: (1) tMCAO group (received an equal volume of 0.9% saline), (2) Poliumoside-L low-dose group (5mg/kg/day), (3) Poliumoside-M middle-dose group (10mg/kg/day), (4) Poliumoside-H high-dose group (15mg/kg/day) and (5) positive control group (EDB 1.5mg/kg) |
Dosage form | 5mg/kg, 10mg/kg, 15mg/kg; ip; 3d |
Applications | Poliumoside improves neurological function and reduces infarct volume after stroke. |
References: | |
| Cas No. | 94079-81-9 | SDF | |
| 别名 | 金石蚕苷 | ||
| 化学名 | [6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-2-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate | ||
| Canonical SMILES | CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OCCC3=CC(=C(C=C3)O)O)O)OC4C(C(C(C(O4)C)O)O)O)OC(=O)C=CC5=CC(=C(C=C5)O)O)O)O)O | ||
| 分子式 | C35H46O19 | 分子量 | 770.73 |
| 溶解度 | ≥ 38.55mg/mL in EtOH | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2975 mL | 6.4874 mL | 12.9747 mL |
| 5 mM | 0.2595 mL | 1.2975 mL | 2.5949 mL |
| 10 mM | 0.1297 mL | 0.6487 mL | 1.2975 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet